Investor Kit

Company Profile

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Stock Chart

Financials

Date Filing Description Download
10/18/18 8-K Current report filing
10/12/18 4 Statement of Changes in Beneficial Ownership
10/11/18 SC 13D/A Amended Statement of Beneficial Ownership
10/09/18 4 Statement of Changes in Beneficial Ownership

Stock Quote

ACOR (Common Stock) $ 17.86 -1.11 (-5.85%) Volume: 669,509 MORE October 19, 2018

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *





 
Enter the code shown above.